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Introduction
The cooking of meat results in the formation of heterocyclic amines (HCA), with the most abundant one being 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP) (Felton et al., 1986; Murray et al., 1993) . In animal studies PhIP has been shown to increase the incidence of mammary and colon cancers (Ito et al., 1991) . Consequently, it has been postulated that exposure of humans to HCA such as PhIP through their diet could be a major determinant of breast cancer incidence. Epidemiological studies examining the potential association of PhIP with the incidence of human breast cancer have given inconsistent results, with some studies suggesting increased risk Steck et al., 2007; Taylor et al., 2007) while others found no association (Delfino et al., 2000; Kabat et al., 2009 ). Elucidating the mechanisms by which PhIP can drive breast carcinogenesis would greatly facilitate the assessment and management of risk to exposed human populations.
PhIP is primarily metabolised through the action of CYP1A2 to the N-hydroxy derivative (Zhao et al., 1994) . This metabolite is then esterified to an unstable nitrenium ion that attacks and forms adducts with guanine bases of DNA (Crosbie et al., 2000; Rindgen et al., 1995; Zhao et al., 1994) . The DNA adducts can eventually lead to mutations. Indeed, in a variety of bacterial and mammalian systems PhIP was demonstrated to be a DNA damaging and mutagenic agent (Felton and Knize, 1991) YadollahiFarsani et al., 1996) , (Boyce et al., 2004; Boyce, 2014) . The DNA-damaging and mutagenic properties of PhIP are therefore one mechanism by which the chemical can cause cancer. Independently from its DNA damaging activity, work in our laboratory (Gooderham et al., 2002; Lauber et al., 2004; Gooderham, 2007, 2011) and by others (Bennion et al., 2005; Okudaira et al., 2013) identified PhIP as a potent stimulator of oestrogen receptor alpha (ERα), but not oestrogen receptor beta (ERβ). Oestrogen induces multiple important biological responses in exposed breast cancer cells and is an established risk factor for breast cancer (Ali and Coombes, 2002) . The ability of PhIP to activate ERα therefore represents an alternative, epigenetic mechanism, through which PhIP may drive breast carcinogenesis. However, two studies have questioned whether PhIP can indeed exert oestrogen hormone-like effects (Evans et al., 2010; Immonen et al., 2009 ) and therefore the ability of PhIP to act as a xenoestrogen is controversial.
MicroRNAs (miRNAs) are a class of non-coding genes that repress posttranscriptionally their target genes and are known to regulate cellular phenotypes such as proliferation, differentiation, apoptosis, and senescence.
Dysregulation of miRNA has been implicated in various human diseases, including cancer (Mendell and Olson, 2012) and occurs following treatment with carcinogenic chemicals (Koufaris et al., 2012) . A number of studies have reported that oestrogenic treatments result in altered miRNA expression in breast cancer cell lines (Klinge, 2012) . Oestrogen regulates its target miRNA by diverse mechanisms, including the direct binding to oestrogen response element (ERE) in the promoters and enhancers of miRNA (Cicatiello et al., 2010) , by affecting biogenesis and processing of miRNA (Paris et al., 2012) or indirectly through the action of its target genes (Castellano et al., 2009 ).
Functional studies have linked oestrogen-induced deregulation of miRNA with phenotypic changes that contribute to breast carcinogenesis (Castellano et al., 2009; Chu et al., 2014; Pinho et al., 2013) . Consequently, it is possible that aberrant miRNA expression induced by activation of ERα by PhIP could be an important factor in the carcinogenesis induced by the chemical.
However, it should be noted that PhIP has also been reported to affect cellular pathways by mechanisms that are independent of ERα (Creton et al., 2007) .
To date no published studies have investigated the effects of PhIP exposure on the expression of miRNA in mammary cells. In this study we examined the effects of exposure to this potent mammary carcinogen on global miRNA expression in the oestrogen responsive and ER expressing MCF-7 breast cancer cell line. PhIP exposure induces rapid changes in target genes and pathways (Lauber et al., 2004) therefore we chose to look at acute (4-24 h) time points. Although several studies have examined the effects of E2 on the expression of miRNA, the reported effects are inconsistent (Klinge, 2012) .
The inter-study variability is probably due to differences in time and dose of treatment, as well as the chosen cell culture conditions. Therefore, in order to investigate the degree to which the PhIP-induced alterations were associated with the oestrogen receptor, we also performed parallel treatments with 17-β-estradiol (E2). Our findings demonstrate that PhIP exposure leads to altered expression of miRNA that has a strong similarity to alterations induced by exposure to E2 and indicate that deregulation of miRNA could be an important epigenetic mechanism contributing to the carcinogenic properties of the chemical.
Material & Methods

Cell culture
The MCF-7 cell line used here was obtained from the European Collection of Cell Cultures. The cells were routinely maintained in minimal essential media supplemented with non-essential amino acids (MEM, Invitrogen), 10% FBS (Invitrogen), 2 mM L-glutamine (Invitrogen), and 100 IU/ml penicillin/100g/ml streptomycin (Invitrogen) in an incubator maintained at 5% CO 2 and 37C.
MCF-7 cells were cultured in phenol red-free MEM supplemented with 10% dextran coated charcoal stripped serum (DCCSS), 2 mM L-glutamine, and 100 IU/ml penicillin/100g/ml streptomycin. To prepare the serum DCCSS dextran-coated charcoal (Sigma-Aldrich) was first added to FBS and left to stir overnight at 4ºC. The solution was then centrifuged at 1000 rpm for 20 minutes at 4ºC, followed by decanting of FBS. The whole process was repeated twice. Finally the DCCSS was centrifuged for 30 minutes at 3000rpm and filtered twice (0.2 μM filter). Dilutions of PhIP (Toronto Research chemicals) and E2 (Sigma-Aldrich) in absolute ethanol were added to each well at the appropriate dosage, with the final ethanol concentration set at 1%.
For control cells the media was supplemented with absolute ethanol (final concentration 1%). All experiments were performed in triplicate.
E-Screen
An E-SCREEN assay was performed following the method of Soto et al. (Soto et al., 1994) , with modifications. Cells were seeded into 6-well plates at a density of 2.5 x 10 5 cells/well in DCSS supplemented media. The following day the media in the wells was replaced with DCSS media containing the tested compounds or ethanol vehicle. The treated cells were harvested after 24, 48 and 72 hours and cell counts were performed using a Neubauer haemocytometer and trypan blue stain (Sigma-Aldrich).
RNA extraction
Total RNA was extracted from cells using Trizol (Invitrogen), following the manufacturer's instructions. A Nanodrop ND-1000 was used to quantify the extracted RNA and evaluate the purity of the RNA solution by determining the 260:280 and 260:230 ratios. The integrity of the isolated RNA was evaluated using the RNA 6000 Nano kit (Agilent) analysed on an Agilent Bioanalyser 2100 (Agilent). RNA was used for subsequent analysis only if it had an RNA integrity number greater than eight and a 260:280 ratio greater than 2.0.
MiRNA microarrays
For the microarray experiments MCF-7 cells were treated as described previously (Lauber et al., 2004) 
Statistical Analysis
Statistical analysis was performed using ANOVA with Tukey or Dunnet's posttest.
Results
E-Screen for 17-β-estradiol and PhIP
The E-screen is a well-established assay for oestrogenic activity (Soto et al., 1994) . The basis of this assay is that MCF-7 cells are growth-inhibited in media containing DCCSS human serum and will only proliferate in the presence of E2 or chemicals with oestrogenic properties. In our previous study, treatment with PhIP resulted in a concentration dependent increase in MCF-7 proliferation (Lauber et al., 2004 (Fig.1A) . No significant proliferative response was observed at any time-point in response to treatment with the highest PhIP dose tested here, 10 -6 M. As expected, a nonmonotonic proliferative response was also observed for E2 under these conditions (Fig.1B) .
Effect of E2 and PhIP on miRNA expression in MCF-7 cells
The doses of E2 (10 -8 M) and PhIP (10 -7 M) which resulted in the strongest proliferative response in MCF-7 cells in the E-SCREEN ( This analysis confirmed a high degree of concordance between microarray and qRT-PCR for these miRNA (Fig.2C) .
Importantly, there was a significant overlap in the miRNA deregulated by PhIP and E2 at each time-point (Fig.3A-D) , with 15 out of 24 miRNA responsive to PhIP also being responsive to E2. Overall, despite the presence of some variability, the direction and magnitude of response for the majority of the miRNA were consistent across the four examined time-points (Tables 1-2 and 
Discussion
Expanding on our previous work we showed that PhIP induced time and dose-dependent increased proliferation of MCF-7 cells (Fig.1) , confirming the ability of the chemical to act as a xenoestrogen. By using a wider-range of concentrations we also showed for the first time that proliferation in the ESCREEN in response to PhIP stimulation is of a non-monotonic nature (Fig.1A) . A similar non-monotonic response was also observed in response to E2 treatment (Fig.1B) in the same MCF-7 cell line. Importantly, the nonmonotonic response to both treatments was observed at all examined timepoints, supporting the validity of this response in our experimental setup.
Non-monotonic responses to hormones and endocrine-disrupting chemicals, including E2, are a matter of ongoing debate in regards to their validity and relevance (Vandenberg et al., 2012 ) (Rhomberg and Goodman, 2012) . In this study the mechanistic basis for the observed non-monotonic response to the two chemicals was not explored, but could include activation of distinct ERα-independent signalling pathways as well as negative feedback loops that could be linked with the notable decrease of the proliferative response at the highest dose for both treatments. It is therefore probable that the observed non-monotonic responses to PhIP and E2 share a similar mechanism, based on the shape of the dose-response curves.
Activity of ERα is known to affect miRNA by diverse mechanisms that include direct binding to promoters and enhancer elements to activate transcription and by affecting miRNA processing (Klinge, 2012) . It was shown in this study for the first time that PhIP exposure elicits wide-spread effects on the miRNAome of a breast cancer cell line (Table 1) . Importantly, miRNA that were responsive to PhIP were also affected by E2 treatment (for example miRs-21, -663, -638, -330-5p, -518C*, -574-5p, 923) ( Table 2 ; Fig.3 and 4) .
The similar effects of PhIP and E2 treatments on miRNA expression that are determined here (Tables 1-2) provide grounds for PhIP driving miRNA deregulation through the activation of ERα. For at least one of the commonly affected miRNA, miR-21, it has been reported that it is transcriptionally regulated by ERα (Wickramasinghe et al., 2009 ). However, in the absence of additional experimental data it is not possible to differentiate between miRNA expression changes that are directly mediated by ERα and those that stem from secondary events. Discrimination between direct and indirect miRNA regulation by the activated ERα would require additional experiments such as chromatic immunoprecipitation. It was also observed that the majority of the miRNA affected by the treatments displayed reduced expression (Tables 1-2) .
A more wide-spread repression of miRNA rather than upregulation following E2 treatment in breast cancer cells is consistent with some studies (Maillot et al., 2009 ) (Yu and Snyderwine, 2002) , but not others (Klinge, 2012) . It has been suggested that the repression of miRNA by E2 is involved in the increased proliferation of mammary cells when stimulated with the hormone (Maillot et al., 2009; Yu et al., 2012) .
At the same time, there were also differences in the miRNA profiles of MCF-7 cells treated with PhIP and E2, as evidenced by clustering of samples and miRNA affected by only one treatment ( Fig.2B; Fig.3) . A potential difference between PhIP and E2 is the DNA adduct forming properties of the former. In vivo the genotoxicity of PhIP is dependent on metabolism by the CYP1 enzymes. The MCF-7 cell line possesses active CYP1A enzymes that can metabolise PhIP to its DNA-reactive form. However, the PhIP doses used in this study are much lower than the micromolar levels that are required for such genotoxic activity. It is also the case that the miRNA affected by PhIP in this study are different to those that have been reported to be affected by DNA damage signalling e.g. the induction of the miR-34 family by p53 (He et al., 2007) . In fact, our study shows a stronger induction for miR-34b for E2 treated MCF-7 cells after 24 hours compared to PhIP treated cells, that could be a result of the upregulation of p53 and Mdm2 by E2 treatment (Qin et al., 2002) . It is likely that distinct effects of PhIP on miRNA expression are either due to differential degrees of ERα activation or ER-independent effects of the two compounds, rather than the DNA-adduct forming effects of PhIP.
Given that miRNA deregulation can drive breast carcinogenesis (Shimono et al., 2009; Song et al., 2013) it is plausible that the ability of PhIP to deregulate miRNA through activation of ERα could be an important mechanism in PhIPmediated carcinogenesis and be implicated in the phenotypic consequences of exposure to the chemical. PhIP treatment has been reported to upregulate the anti-apoptotic BCL-2 in the mammary gland of rats (Venugopal et al., 1999) . Interestingly, BCL-2 expression has been shown to be repressed in MCF-7 cells by miR-21 (Wickramasinghe et al., 2009 ), miR-16 (Yu et al., 2012 , and miR-24 (Srivastava et al., 2011) , all of which were downregulated by PhIP in this study. PhIP has also been shown to affect metastatic potential in vitro (Lauber and Gooderham, 2011) . In this study PhIP repressed miR200c/141, miRNA that are master regulators of invasiveness and metastasis (Burk et al., 2008) . H-Ras, an oncogene that is mutated in PhIP-induced breast cancer (Yu and Snyderwine, 2002) is also targeted by miR-663 (Yang et al., 2013) , one of the most strongly suppressed miRNA identified in this study. However, whether the miRNA deregulation identified in this study can be extrapolated to in vivo mammary tissue in exposed animals or humans is not clear. Our previous reports show that the effects of xenobiotics on miRNA profiles in vivo are highly dependent on the dose and time of exposure (Koufaris et al., 2013) . Additionally, oestrogenic effects on miRNA expression are reported to be highly variable according to cell culture conditions (Klinge, 2012) .
Two published studies have questioned the ability of PhIP to induce oestrogenic responses in breast cancer cells (Evans et al., 2010; Immonen et al., 2009) (Lauber et al., 2004; Lauber and Gooderham, 2007) . The ability of PhIP to induce oestrogenicdependent responses is also supported by the work of independent labs (Bennion et al., 2005; Okudaira et al., 2013) . Importantly, blocking oestrogenic signalling disrupts the ability of PhIP to induce phenotypic responses in exposed cells (Lauber et al., 2004; Gooderham, 2007, 2011; Okudaira et al., 2013) . Consequently, we consider it highly unlikely that the ability of PhIP to induce oestrogenic-dependent responses identified by ourselves and others is artifactual. It is also important to note that the two contradictory studies did not attempt to replicate the original findings and varied in experimental conditions such as cell type, treatment doses, exposure times, and seeding densities. A further complication is that a variety of MCF-7 sublines exist which differ in their sensitivity to oestrogenic treatments (Villalobos et al., 1995) . The non-monotonic oestrogen response to PhIP (Fig.1) further emphasises the importance of dose and temporal considerations.
A recent study employing a specific assay for PhIP-DNA adducts suggested that the incidence of adduct formation in mammary tissue in humans is relatively low (Gu et al., 2012 ). Yet the tissue specificity of the carcinogenic effects of PhIP involves selectivity for the breast, and suggests that a predominantly genotoxic mechanism of action is unlikely. This is supported by the fact that the reported levels of PhIP exposure anticipated to occur in humans are likely to be below those shown to induce mutagenesis (Lauber et al., 2004; Lynch et al., 1992) , although they are within the range of exposures shown to give rise to measurable PhIP-DNA adducts (Turteltaub et al., 1999) .
Doses of PhIP that are estimated to be within physiologically relevant levels have been reported to activate ERα and induce multiple effects that could contribute to carcinogenesis including increased proliferation, prolactin secretion, invasiveness (Lauber et al., 2004; Gooderham, 2007, 2011) , and long interspersed element-1 (L1) mediated genomic instability (Okudaira et al., 2013) . Whilst the former studies investigating the hormonelike properties of PhIP were based on cell line models (Lauber et al., 2004; Lauber and Gooderham, 2007 ), importantly, Okudaira et al.,(Okudaira et al., 2013 used transgenic mice to detect in vivo ERα-dependent genomic instability caused by PhIP exposure, supporting the biological relevance of this mechanism. The data generated in the present study support these previous reports and demonstrate that in MCF-7 breast cancer cells PhIP exposure can also drive the deregulation of miRNA expression (Fig.2-3 ).
Thus this work adds further mechanistic support to the hypothesis that life-long exposure to low levels of PhIP could increase the incidence of breast cancer through oestrogenic mechanisms. 
